Potentia Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
Formerly started as an early stage nanotechnology company, Potentia Pharmaceuticals Inc. is now focused on developing novel therapeutics for macular degeneration--a disease that affects nearly 20 million people worldwide and that, until only three years ago, had little to no treatment.